Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models
Open accessThe DOI matches its Crossref record; 48 of the 50 references it cites were found in a registry or an index.
Abstract
Bacteria can be genetically engineered to kill specific pathogens or inhibit their virulence. We previously developed a synthetic genetic system that allows a laboratory strain of Escherichia coli to sense and kill Pseudomonas aeruginosa in vitro . Here, we generate a modified version of the system, including a gene encoding an anti-biofilm enzyme, and use the probiotic strain Escherichia coli Nissle 1917 as host. The engineered probiotic shows in vivo prophylactic and therapeutic activity against P. aeruginosa during gut infection in two animal models ( Caenorhabditis elegans and mice). These findings support the further development of engineered microorganisms with potential prophylactic and therapeutic activities against gut infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“For example, Hwang et. al. demonstrated that the EcN-based gastrointestinal delivery of anti-biofilm enzyme, dispersin B (DspB), resulted in a reduction of pre-colonized P. aeruginosa abundance in both nematode and murine models29.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [29]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Regulating effector expression in response to bacterial quorum sensing molecules29, pH30, specific carbon sources31–33, temperature34, or combinations of these signals may allow for exquisitely tuned effector functions in various intestinal microenvironments7.”
From Developing a new class of engineered live bacterial therapeutics to treat human diseases (2020) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products
Datsenko, K. A., & Wanner, B. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120163297 · Cited by 14,782
The Involvement of Cell-to-Cell Signals in the Development of a Bacterial Biofilm
Davies, D. G., Parsek, M. R., Pearson, J. P., Iglewski, B. H., Costerton, J. W., & Greenberg, E. P. (1998) · Science · doi:10.1126/science.280.5361.295 · Cited by 3,396
Ceri, H., Olson, M. E., Stremick, C., Read, R. R., Morck, D., & Buret, A. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.6.1771-1776.1999 · Cited by 2,155
Interdependence of Cell Growth and Gene Expression: Origins and Consequences
Scott, M., Gunderson, C. W., Mateescu, E. M., Zhang, Z., & Hwa, T. (2010) · Science · doi:10.1126/science.1192588 · Cited by 1,470
Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients
Smith, E. E., Buckley, D. G., Wu, Z., Saenphimmachak, C., Hoffman, L. R., D’Argenio, D. A., Miller, S. I., Ramsey, B. W., Speert, D. P., Moskowitz, S. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602138103 · Cited by 1,319
Tan, M.-W., Mahajan-Miklos, S., & Ausubel, F. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.2.715 · Cited by 1,002
Synchronized cycles of bacterial lysis for in vivo delivery
Din, M. O., Danino, T., Prindle, A., Skalak, M., Selimkhanov, J., Allen, K., Julio, E., Atolia, E., Tsimring, L. S., Bhatia, S. N., et al. (2016) · Nature · doi:10.1038/nature18930 · Cited by 784
Refinement and standardization of synthetic biological parts and devices
Canton, B., Labno, A., & Endy, D. (2008) · Nature Biotechnology · doi:10.1038/nbt1413 · Cited by 753
The gastrointestinal tract. The “undrained abscess” of multiple organ failure
Marshall, J. C., Christou, N. V., & Meakins, J. L. (1993) · Annals of Surgery · doi:10.1097/00000658-199308000-00001 · Cited by 707
de Jonge, E., Schultz, M. J., Spanjaard, L., Bossuyt, P. M., Vroom, M. B., Dankert, J., & Kesecioglu, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14409-1 · Cited by 587
Cited by
Items 201–300 of 481
A molecular toolkit for heterologous protein secretion across Bacteroides species
Yeh, Y.-H., Kelly, V. W., Pour, R. R., & Sirk, S. J. (2024) · Nature Communications · doi:10.1038/s41467-024-53845-7 · Cited by 26
Development of bacteria as diagnostics and therapeutics by genetic engineering
Lim, D., & Song, M. (2019) · The Journal of Microbiology · doi:10.1007/s12275-019-9105-8 · Cited by 25
Non-antibiotic therapy forClostridioides difficileinfection: a review
Yang, J., & Yang, H. (2019) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1648377 · Cited by 29
Recent progress in experimental and human disease-associated multi-species biofilms
Bai, F., Cai, Z., & Yang, L. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.09.010 · Cited by 26
“domonas aeruginosa biofilm infection in the gut of animal models [95].”
BackgroundThe Microbiome and Its Potential for Pharmacology
Chavira, A., Belda‐Ferre, P., Kościółek, T., Ali, F., Dorrestein, P. C., & Knight, R. D. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_317 · Cited by 22
Chiacchiera, A. F., Casanova, M., Bellato, M., Piazza, A., Migliavacca, R., Batt, G., Magni, P., & Pasotti, L. (2025) · Scientific Reports · doi:10.1038/s41598-024-81989-5 · Cited by 26
A comprehensive review on utilizing CRISPR/Cas system for microbiome modification
Abavisani, M., Faraji, N., Faraji, S., Ebadpour, N., Kesharwani, P., & Sahebkar, A. (2024) · Biochemical Engineering Journal · doi:10.1016/j.bej.2024.109443 · Cited by 27
Wang, T., Zhou, N., Ding, F., Hao, Z., Galindo‐Villegas, J., Du, Z., Su, X., & Zhang, M. (2024) · Microbiome · doi:10.1186/s40168-024-01934-6 · Cited by 25
“Enzymes, the main products of some specific microbiota, could also regulate intestinal microbial composition and immunity status of animals [7–9].”
BackgroundLiving Engineered Bacterial Therapeutics: Emerging Affordable Precision Interventions
Srivastava, R., & Lesser, C. F. (2024) · Microbial Biotechnology · doi:10.1111/1751-7915.70057 · Cited by 25
Recent advances of engineered probiotics for therapeutic applications
Zhang, L., Chen, N., Chen, H., Tang, C., Wang, J., Wang, Y., Zhang, Y., Guo, H., & Yuan, J. (2025) · BioDesign Research · doi:10.1016/j.bidere.2025.100039 · Cited by 32
“The engineered EcN had prophylactic and therapeutic activity against P. aeruginosa during intestinal infection in two animal models [107].”
Li, N., Yin, L., Wang, J., Zhang, J., & Tong, Y. (2025) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2025.103375 · Cited by 26
Therapeutic microbes to tackle disease
Ainsworth, C. (2020) · Nature · doi:10.1038/d41586-020-00201-6 · Cited by 20
The beneficial effects of genetically engineered Escherichia coli Nissle 1917 in obese C57BL/6J mice
Ma, J., Wang, J., Xu, L., Liu, Y., & Gu, J. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01073-8 · Cited by 22
Microbiome systems biology advancements for natural well-being
Chatterjee, G., Negi, S., Basu, S., Faintuch, J., O’Donovan, A., & Shukla, P. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.155915 · Cited by 24
Guan, C., Larson, P. J., Fleming, E. S., Tikhonov, A. P., Mootien, S., Grossman, T. H., Golino, C., & Oh, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276795 · Cited by 24
“Following the model of recent development of engineered probiotics to combat enteric infections by Pseudomonas [14] and Salmonella [15] pathogens, we sought to develop a skin probiotic to combat MRSA colonization and growth on skin.”
BackgroundInfluentialZhang, H., Chen, B., Wang, Z., Peng, K., Liu, Y., & Wang, Z. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03884-23 · Cited by 20
“…to preventing the introduction of new resistant genes, the chromosome-plasmid-balanced lethal system also provides a method of strain biocontainment, where the resensitization system may promote their clearance after executing their programmed function or when the expression construct is lost (25).”
BackgroundIntestinal interplay of quorum sensing molecules and human receptors
Krasulová, K., & Illéš, P. (2021) · Biochimie · doi:10.1016/j.biochi.2021.06.010 · Cited by 20
Genetically modified bacteria enlisted in fight against disease
Reardon, S. (2018) · Nature · doi:10.1038/d41586-018-05476-4 · Cited by 19
Yang, C., Saiding, Q., Chen, W., An, S., Zhao, S., Khan, M. M., Kong, N., Ge, M., Shi, J., Lin, H., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01600-8 · Cited by 36
He, L., Tang, W., Huang, L., Zhou, W., Huang, S., Zou, L., Yuan, L., Men, D., Chen, S., & Hu, Y. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10449 · Cited by 24
Marsh, J. W., Kirk, C., & Ley, R. E. (2023) · Annual Review of Microbiology · doi:10.1146/annurev-micro-032421-112304 · Cited by 23
Wang, Y., Shi, Y., Peng, X., Li, T., Liang, C., Wang, W., Zhou, M., Yang, J., Cheng, J., Zhang, Z., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303958 · Cited by 22
Synthetic Biology‐Based Engineering Living Therapeutics for Antimicrobial Application
Huang, S., Zhao, S., Zhao, H., Wen, M., & Guo, Z. (2025) · Exploration · doi:10.1002/exp.20240045 · Cited by 26
Maor, M., Barazany, H. L., & Kolodkin‐Gal, I. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2517377 · Cited by 19
“43 Another approach is the introduction of a synthetic circuit that controls bacterial growth, activating it only in response to an external signal that does not interfere with mammalian cells or is a part of the culture media.”
Shahid, U. (2025) · The Journal of Precision Medicine Health and Disease · doi:10.1016/j.premed.2025.100018 · Cited by 35
Dapgh, A. N., Hakim, A. S., Abouelhag, H., Abdou, A. M., & Elgabry, E. A. (2019) · Veterinary World · doi:10.14202/vetworld.2019.1524-1528 · Cited by 24
“aeruginosa infection may lead to urogenital disorders, gastrointestinal illness sinusitis, and osteomyelitis [5-8].”
BackgroundBacteria-Based Microdevices for the Oral Delivery of Macromolecules
Cao, Z., Lin, S., & Liu, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101610 · Cited by 18
“In addition, EcN is programmed to pro uce an anti-biofilm protein, dispersin B (DspB), which is able to disrupt the integrity of mature iofilms [59,103].”
BackgroundInfluentialComparative Genomics and Pan-Genome Driven Prediction of a Reduced Genome of Akkermansia muciniphila
Bukhari, S. A. R., Irfan, M., Ahmad, I., & Chen, L. (2022) · Microorganisms · doi:10.3390/microorganisms10071350 · Cited by 18
“The potential health benefits of probiotics have attracted much interest in engineering more useful and robust microbes that can produce a variety of beneficial metabolites and fight against pathogens [14,15].”
BackgroundRobinson, C. M., Short, N. E., & Riglar, D. T. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.959441 · Cited by 17
“In the context of the gut, spatial activation at infection sites can be achieved by repurposing pathogens’ own QS mechanisms (Saeidi et al., 2011; Gupta et al., 2013; Hwang et al., 2014; Hwang et al., 2017; Jayaraman et al., 2017).”
BackgroundGui, W., Guo, H., Chen, X., Wang, J., Guo, Y., Zhang, H., Zhou, X., Zhao, Y., & Dai, J. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.114368 · Cited by 22
Engineered Bacteria: General Overview as Therapeutic Agent and a Novel Drug Delivery System
Patil, P. L., Gharat, S. K., Jadhav, K. R., & Kadam, V. J. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201024666221220113517 · Cited by 18
Kim, H. J., Jang, J. H., Jung, I. Y., Kim, H. R., & Cho, J. H. (2023) · Biomedicines · doi:10.3390/biomedicines11102645 · Cited by 19
“Hwang et al. improved this system by adding the anti-biofilm enzyme dispersin B, also controlled by P las and implemented in EcN [31].”
MethodHauk, P., Stephens, K., Virgile, C., VanArsdale, E. S., Pottash, A. E., Schardt, J. S., Jay, S. M., Sintim, H. O., & Bentley, W. E. (2020) · ACS Synthetic Biology · doi:10.1021/acssynbio.0c00179 · Cited by 19
Self-citationGemler, B. T., Mukherjee, C., Howland, C. A., Huk, D. J., Shank, Z., Harbo, L. J., Tabbaa, O. P., & Bartling, C. M. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.979497 · Cited by 18
“Exemplar chassis, such as Escherichia coli have been engineered with numerous functions, such as those to sense other bacteria, breakdown biofilms, and release toxic payloads (Hwang et al., 2017).”
BackgroundLiang, M., Zhang, J., Yang, Y., Yi, X., Liu, L., Liu, L., Wang, Q., & Gao, X. (2022) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-022-03452-9 · Cited by 18
Liu, M., Li, N., Shan, S., Shi, Y., Zhu, Y., & Lu, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095034 · Cited by 17
“elegans—PA14 infection model is currently a novel and excellent model in studying immune-boosting drugs [7].”
BackgroundWu, F., Shi, Z., Lei, H., Chen, G., Yuan, P., Cao, Z., Chen, C., Zhu, X., Liu, C., Dong, M., et al. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c05921 · Cited by 18
Toward a systematic design of smart probiotics
Choudhary, R., & Mahadevan, R. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.05.003 · Cited by 17
Genetically Engineered Bacteria for Treating Human Disease
Ma, B., Pan, Q., & Peppelenbosch, M. P. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.07.001 · Cited by 17
Salman, J. A. S., Mahmood, N. N., Abdulsattar, B. O., & Abid, H. A. (2020) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2020.5483 · Cited by 16
“coli Nissle 1917 [33], [34] Propionibacterium P.”
Jia, G., Liu, X., Zhi, A., Li, J., Wu, Y., & Zhang, Y. (2021) · AMB Express · doi:10.1186/s13568-021-01245-1 · Cited by 19
Combating Infectious Diseases with Synthetic Biology
Khan, A., Ostaku, J., Aras, E., & Şeker, U. Ö. Ş. (2022) · ACS Synthetic Biology · doi:10.1021/acssynbio.1c00576 · Cited by 17
Synthetic Biology-Based Approaches to Investigate Host–Pathogen Interactions
Banerjee, R. (2025) · SynBio · doi:10.3390/synbio3010004 · Cited by 17
“In a recent study, Hwang et al. engineered the E. coli Nissle strain to target and kill P. aeruginosa by delivering an antimicrobial peptide and a biofilm-dispersing enzyme [118].”
Lebovich, M., Zeng, M., & Andrews, L. B. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.3c00232 · Cited by 16
Durmusoglu, D., Haller, D. J., Al’Abri, I. S., Day, K., Sands, C., Clark, A. S., San‐Miguel, A., Vazquez-Uribe, R., Sommer, M. O. A., & Crook, N. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00145 · Cited by 16
Borralho, J., Handem, S., Lança, J., Ferreira, B., Candeias, C., Henriques, A. O., Hiller, N. L., Valente, C., & Sá‐Leão, R. (2025) · Applied and Environmental Microbiology · doi:10.1128/aem.01336-24 · Cited by 20
“…probiotic Escherichia coli strains able to reduce vancomycin-resistant enterococci and Pseudomonas aerugi nosa in the gut of animal models (17, 18); (ii) a phase 1 randomized clinical trial, where a Staphylococcus hominis strain reduced the bacterial load of Staphylococcus aureus in the skin…”
Genetic circuitry for personalized human cell therapy
Tölle, F., Stücheli, P., & Fussenegger, M. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.02.003 · Cited by 17
The Response of Pseudomonas aeruginosa PAO1 to UV-activated Titanium Dioxide/Silica Nanotubes
Augustyniak, A., Cendrowski, K., Grygorcewicz, B., Jabłońska, J., Nawrotek, P., Trukawka, M., Mijowska, E., & Popowska, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207748 · Cited by 14
“aeruginosa have the potential to be used against bacteria resistant to antibiotics [27,28].”
BackgroundExploiting enzymes as a powerful tool to modulate the gut microbiota
Su, X., & Yao, B. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2022.01.003 · Cited by 14
Methods of DNA introduction for the engineering of commensal microbes
Liu, D., Siguenza, N., Zarrinpar, A., & Ding, Y. (2022) · Engineering Microbiology · doi:10.1016/j.engmic.2022.100048 · Cited by 16
“For instance, antimicrobial activities of EcN have been enhanced by overproducing its native or non-native bacteriocins [ 37 , 83 ] or releasing quorum sensing molecules [ 28 , 46 ].”
Biofilms and Benign Colonic Diseases
Songtanin, B., Peterson, C., Molehin, A. J., & NUGENT, K. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214259 · Cited by 16
Engineering bacterial theranostics: from logic gates to in vivo applications
Armstrong, A., & Isalan, M. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1437301 · Cited by 18
Leveraging strain competition to address antimicrobial resistance with microbiota therapies
Steed, D. B., Koundakjian, D., Harris, A. D., Rosato, A. E., Konstantinidis, K. T., & Woodworth, M. H. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2488046 · Cited by 15
Modiri, S., Kermanshahi, R. K., Soudi, M. R., Arab, S. S., Khammari, A., Cousineau, B., Vali, H., Zahiri, H. S., & Noghabi, K. A. (2020) · Applied and Environmental Microbiology · doi:10.1128/aem.00367-20 · Cited by 13
“Pseudomonas aeruginosa is recognized as one of the most dangerous threats to human health; it is classified as one of the bacteria in the ESCAPE list of the Centers for Disease Control and Prevention (12).”
BackgroundInducible directed evolution of complex phenotypes in bacteria
Al’Abri, I. S., Haller, D. J., Li, Z., & Crook, N. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac094 · Cited by 14
“coli Nissle 1917 is a probiotic strain (5,47,48).”
Hare, P. J., Englander, H. E., & Mok, W. W. K. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15541 · Cited by 15
“coli Nissle strains, similar to the approach that Hwang and colleagues used (Hwang et al., 2017).”
BackgroundResultInfluentialRitter, S. C., Yang, M. L., Kaznessis, Y. N., & Hackel, B. J. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26772 · Cited by 13
“…Salomón, & Farías, 2007), or secreted via engineered probiotics at the site of infection (Borrero, Chen, Dunny, & Kaznessis, 2014; Forkus, Ritter, Vlysidis, Geldart, & Kaznessis, 2017; Geldart, Borrero, & Kaznessis, 2015; Geldart, Forkus, McChesney, McCue, & Kaznessis, 2016; Hwang et al., 2017).”
BackgroundElectronic signals are electrogenetically relayed to control cell growth and co-culture composition
Stephens, K., Zakaria, F. R., VanArsdale, E. S., Payne, G. F., & Bentley, W. E. (2021) · Metabolic Engineering Communications · doi:10.1016/j.mec.2021.e00176 · Cited by 13
Self-citationZhao, L., Xin, J., Hu, M., Xue, C., & Dong, N. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.10.028 · Cited by 19
“When the concentration of E7 reaches the threshold, it can lyze the host bacteria and release antimicrobial peptides, thereby achieving targeted bactericidal effect [133,134].”
Enhancing the antibacterial function of probiotic Escherichia coli Nissle: when less is more
Bartram, E., Asai, M., Gabant, P., & Wigneshweraraj, S. (2023) · Applied and Environmental Microbiology · doi:10.1128/aem.00975-23 · Cited by 13
“This is becoming an emerging alternative strategy to promote the clearance of various enteric pathogens with, so far, successful application in different animal models (15–17).”
BackgroundChamas, A., Svensson, C., Maneira, C., Sporniak, M., Figge, M. T., & Lackner, G. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00466 · Cited by 15
Heer, K., Kaur, M., Sidhu, D., Dey, P., & Raychaudhuri, S. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1452784 · Cited by 12
“Similar effects were reported against the colonization of Salmonella typhimurium (18) and Pseudomonas aeruginosa (19) which were likely mediated by the potent iron chelation properties of ECN (20).”
ResultConstructing reality with models
Tee, S.-H. (2018) · Synthese · doi:10.1007/s11229-017-1673-8 · Cited by 15
“…activity produced by dispersin B (Dsp B), which is a 40 kDa highly active and stable single-chain glycoside hydrolase (Ramasubbu et al. 2005), and the presence of the anti-microbial protein pyocin S5 in the engineered model jointly exhibit significant P. aeruginosa clearance (Hwang et al. 2017).”
BackgroundMethodResultInfluentialConstructing Synthetic Ecosystems with Biopolymer Fluitrodes
Pham, P., Rooholghodos, S. A., Choy, J. S., & Luo, X. (2018) · Advanced Biosystems · doi:10.1002/adbi.201700180 · Cited by 13
Advances in Bacterial Biofilm Management for Maintaining Microbiome Homeostasis
Liu, Z., Hong, C., Yang, Y., Dai, L., & Ho, C. L. (2020) · Biotechnology Journal · doi:10.1002/biot.201900320 · Cited by 13
Unveiling the Mechanisms of Bacterial Resistance and Countermeasures
Xie, Y., Lu, H., Liu, Y., Hu, G., Lian, S., Liu, J., Pang, S., Zhu, G., & Ding, X. (2025) · Pathogens · doi:10.3390/pathogens14111085 · Cited by 21
“Genetically modified probiotics, such as engineered E. coli Nissle 1917, enhance efficacy against P. aeruginosa infections [172].”
Composition and Function of Gut Microbiome: From Basic Omics to Precision Medicine
Ma, Y., Wang, L., Hu, H., Shieh, A. R.-E., Li, E., He, D., He, L., Liu, Z., Paing, T. M., Chen, X., et al. (2026) · Genes · doi:10.3390/genes17010116 · Cited by 13
“For example, applying the probiotic Escherichia coli Nissle 1917 as the host in model animals revealed its impact on Pseudomonas aeruginosa within the body [131].”
Clinical application of live biotherapeutic products in infectious diseases
Navalkele, B. D., & Chopra, T. (2024) · Frontiers in Microbiomes · doi:10.3389/frmbi.2024.1415083 · Cited by 14
Remotely Controllable Engineered Bacteria for Targeted Therapy of Pseudomonas aeruginosa Infection
Gao, Y., Wei, J., Pu, L., Fu, S., Xing, X., Zhang, R., & Jin, F. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.2c00655 · Cited by 11
Microbes little helpers and suppliers for therapeutic asthma approaches
Reuter, S., Raspe, J., & Taube, C. (2024) · Respiratory Research · doi:10.1186/s12931-023-02660-7 · Cited by 13
“This is especially the case for bacteria such as Escherichia coli Nissle [19], Lactobacillus or Lactococcus [20], which tend to induce anti-inflammatory immune responses in the host and are not capable of long-term colonization.”
BackgroundSynthetic receptors to understand and control cellular functions
Chang, H., & Bonnet, J. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.11.011 · Cited by 14
Nam, J., Lee, Y., Lee, S., Choi, H., Lee, S. Y., & Yang, D. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108782 · Cited by 14
Self-citationHao, X., Chen, J., Li, Y., Liu, X., Li, Y., Wang, B., Cao, J., Gu, Y., Ma, W., & Ma, L. (2023) · Cells · doi:10.3390/cells12040543 · Cited by 11
“Then, we collected PWNs and washed them with M9 buffer from the petri dishes [24].”
MethodEngineering Escherichia coli for diagnosis and management of hyperuricemia
Gencer, G., Mancuso, C. P., Chua, K. J., Ling, H., Costello, C. M., Chang, M. W., & March, J. C. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1191162 · Cited by 12
“Engineered microbes can provide non-invasive, cost-effective, and on-site diagnosis and treatment for various human diseases (Archer et al., 2012; Kotula et al., 2014; Duan et al., 2015; Hwang et al., 2017).”
BackgroundSelf-citationPrecision microbial regulation: Strategies for modulating GIT microbiota for host health
Pei, Z., Li, Q., Zhang, Y., Guo, C., Abdelsattar, M. M., & Bi, Y. (2025) · iMetaOmics. · doi:10.1002/imo2.54 · Cited by 12
“…into GEMs with antimicrobial function to detect specific signaling molecules produced by pathogens, thereby enabling targeted disease control [91, 92]; (2) Reprogramming the metabolic pathways of GEMs to produce beneficial metabolites or degrade harmful sub-stances [48, 93]; (3) Enhancing…”
Gao, X., Sun, Y., Yang, Y., Yang, X. X., Liu, Q., Guo, X., Wu, L., & Wang, Q. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142250 · Cited by 13
A multilayered biocontainment system for laboratory and probiotic yeast
Maneira, C., Becker, S., Chamas, A., & Lackner, G. (2025) · Metabolic Engineering · doi:10.1016/j.ymben.2025.06.009 · Cited by 13
Abavisani, M., Sajjadi, S. M., Ebadpour, N., Kesharwani, P., Karav, S., & Sahebkar, A. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.165777 · Cited by 10
Tresnak, D. T., & Hackel, B. J. (2020) · Applied and Environmental Microbiology · doi:10.1128/aem.01646-20 · Cited by 11
Combinatorial leaky probiotic for anticancer immunopotentiation and tumor eradication
Liu, C., Pan, Y., Lim, S.-K., Mou, C., Hu, C. J., & Mou, Y. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101793 · Cited by 13
“As bacterial therapies are witnessing growing adoption in oncological 43 and other diseases including metabolic disease, 44,45 infectious disease, 46 and in-flammatory disease, 47,48 the robust cargo-releasing attributes and improved safety profile afforded by the lpp gene knockout make the leaky…”
Dey, S., Seyfert, C. E., Fink‐Straube, C., Kany, A. M., Müller, R., & Sankaran, S. (2024) · Journal of Biological Engineering · doi:10.1186/s13036-024-00463-y · Cited by 12
“…for the thermoresponsive genetic circuit based on the high-copy number pUC replication origin, we chose this recombinant construct for assessing the two commonly employed plasmid retention strategies based on nutrient auxotrophy [42] and toxin-antitoxin dependent post-segregational killing [43].”
Li, H., Zhang, S., Yin, J., Wang, G., Wang, Q., Xia, Y., Li, L., Qi, Q., & Wang, Q. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2530156 · Cited by 9
“31 Herein, we designed two simplified logic gates in the engineered EcN probiotic targeting and inhibiting the growth of P. aeruginosa and Y. enterocolitica in vitro by simultaneously responding to two signals C 12 and C 6 .”
Microbiome engineering: unlocking therapeutic potential in inflammatory bowel disease
Chen, K., Huang, L.-B., Yang, M., Yue, N.-N., Luo, D., Zhang, Y., Tian, C., Song, Y., Wei, D., Shi, R., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1610029 · Cited by 17
Establishing a Multivariate Model for Predictable Antisense RNA-Mediated Repression
Lee, Y. J., Kim, S.-J., Amrofell, M. B., & Moon, T. S. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00227 · Cited by 10
Self-citationJin, X., An, S., Kightlinger, W., Zhou, J., & Hong, S. H. (2021) · AIChE Journal · doi:10.1002/aic.17466 · Cited by 8
“coli Nissle 1917 secreting pyocin S5 and antibiofilm enzyme DspB has been found to eliminate and prevent Pseudomonas aeruginosa gut infection in an animal model.(15) These findings demonstrate that live biotherapeutics based on engineered microorganisms are promising approaches to overcome the limitations of drug degr…”
BackgroundDas, N. C., Patra, R., Dey, A., & Mukherjee, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-8990-1_5 · Cited by 11
Park, J., Kwak, M., Kang, M.-G., Cho, D.-Y., Kim, J. N., Choi, I., & Kim, Y. (2024) · Journal of environmental chemical engineering · doi:10.1016/j.jece.2024.113977 · Cited by 10
Skin microbiome engineering: Challenges and opportunities in skin diseases treatment
Lyu, Y., Shen, J., Che, Y., & Dai, L. (2025) · iMetaOmics. · doi:10.1002/imo2.70012 · Cited by 10
“Researchers used gene editing on the probiotic strain E. coli Nissle 1917 as a host, showing in vivo prevention and treatment activity against Pseudomonas aeruginosa during gut infection in two animal models ( C. elegans and mice) [157].”
A genetic safeguard for eliminating target genes in synthetic probiotics in a gut environment
Nguyen, N., Wang, M., Li, L., & Chan, C. T. Y. (2025) · iScience · doi:10.1016/j.isci.2025.113027 · Cited by 15
“34 We developed this strategy in Escherichia coli Nissle 1917 ( EcN ), which is a well-studied probiotic strain that has been engineered for diagnosis and treatments of infectious diseases, 35 gut inflammation, 36,37 tumors, 38,39 and a genetic disease.”
Wang, L., Ren, S., Behan, A. A., Buzdar, J. A., Arain, M. A., & Li, Y. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10883-x · Cited by 16
“Approaches include heterologous expression of AMPs from unrelated species, deletion of regulatory repressors to upregulate native biosynthetic pathways, and development of gene circuits that sense and respond dynamically to pathogen-associated signals in the gastrointestinal tract [ 17, 66].”
Ma, C., Li, G., Sun, T., Tang, X., Qiu, T., Song, J., Wang, H., Zhang, Y., & Jiang, T. (2026) · PLoS Biology · doi:10.1371/journal.pbio.3003657 · Cited by 9
“Additionally, harnessing programmed bacterial cell lysis could enhance FK228 diffusion and efficacy [86,87].”
Engineering microbial living therapeutics
Pedrolli, D. B., Ribeiro, N. V., Squizato, P. N., Cozetto, D. A., de Jesus, V. N., Freire, P. J. C., Lins, M. R. C. R., & Corrêa, G. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819178-1.00008-3 · Cited by 6
Application of Bacterial Whole-Cell Biosensors in Health
Song, Y., Rampley, C. P. N., Chen, X., Du, F., Thompson, I. P., & Huang, W. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-23217-7_136 · Cited by 10
Gut microbiome and neurosurgery: Implications for treatment
Willman, J., Willman, M., Reddy, R., Fusco, A. F., Sriram, S., Mehkri, Y., Charles, J. H., Goeckeritz, J., & Lucke-Wold, B. P. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.139 · Cited by 10
Singh, A., Mazumder, A., Das, S., Kanda, A., Tyagi, P. K., & Chaitanya, M. (2024) · Recent Advances in Anti-Infective Drug Discovery · doi:10.2174/0127724344308638240530065552 · Cited by 8
Pierro, F. D., Thacharodi, A., Kumaraswami, M., Suvorov, A. N., Zupet, J., & Zerbinati, N. (2026) · Microbial Cell Factories · doi:10.1186/s12934-026-02997-w · Cited by 12
“…release of pyocin S5 together with the anti-biofilm enzyme dis-persin B, thereby extending an earlier designer-bacte-ria delivery concept into a probiotic chassis [95]; other Nissle 1917 constructs reduced intestinal colonization by vancomycin-resistant E. faecalis and E. faecium [96].”
An engineered genetic circuit for lactose intolerance alleviation
Cheng, M., Cheng, Z., Yu, Y., Liu, W., Li, R., Guo, Z., Qin, J., Zeng, Z., Di, L., Mo, Y., et al. (2021) · BMC Biology · doi:10.1186/s12915-021-01070-9 · Cited by 7
“Moreover, engineered bacteria are believed to work more precisely and efficiently in addressing these diseases [19] as compared to wild-type bacteria.”
BackgroundDevi, S., Chhibber, S., & Harjai, K. (2022) · 3 Biotech · doi:10.1007/s13205-022-03187-2 · Cited by 7
“aeruginosa such as gastrointestinal tract (Hwang et al. 2017), pulmonary (Alexandre et al.”
BackgroundWang, X.-G., Zou, Z., Du, Y., Ye, B., & Zhou, Y. Q. (2023) · ACS Synthetic Biology · doi:10.1021/acssynbio.3c00445 · Cited by 7
Progress towards the clinical use of antimicrobial peptides: challenges and opportunities
Espinal, P., Fusté, E., Sierra, J. M., Jiménez-Galisteo, G., Vinuesa, T., & Viñas, M. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2226796 · Cited by 8
“Probiotics are not considered as pharmaceuticals, but as functional foods or nutraceuticals, so the development of these probiotics, even for local infections, such as intestinal infections as suggested by the aforementioned authors [37,38] would not follow the strict regulations for the development of antibiotics, bu…”
Background
Metadata
- Authors
- Hwang, I. Y., Koh, E., Wong, A., March, J. C., Bentley, W. E., Lee, Y. S., & Chang, M. W.
- Affiliations
- National University of Singapore (SG)
- Cornell University (US)
- University of Maryland, College Park (US)
- Corresponding author
- Chang, Matthew Wook
- ORCID
- Venue
- Nature Communications
- Published
- 2017-04-11
- Volume
- 8
- Issue
- 1
- Pages
- 15028-15028
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5394271
- OpenAlex
- W2605968366
- Cited by
- 472
- References
- 50
- Citations by year
- 2026: 44 · 2025: 53 · 2024: 51 · 2023: 55 · 2022: 68 · 2021: 44 · 2020: 54 · 2019: 53 · 2018: 41 · 2017: 9
- FWCI
- 31.49
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National University of Singapore (DPRT/943/09/14)
- National University Health System
- Defense Threat Reduction Agency (HDTRA1‐13‐0037, HDTRA1, DPRT/943/09/14)
- U.S. Air Force
- Medical Research Council
- National Medical Research Council (CBRG11nov109)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Keywords
- engineered probiotics, Escherichia coli, Pseudomonas aeruginosa, intestinal infection, Escherichia coli Nissle 1917, prophylaxis, therapeutic activities, Caenorhabditis elegans, mouse model
- MeSH terms
- Microorganisms, Genetically-Modified, Animals, Disease Models, Animal, Escherichia coli, Female, Gastroenteritis, Genetic Engineering, Mice, Inbred ICR, Pseudomonas aeruginosa, Pseudomonas Infections, Virulence, Caenorhabditis elegans, Probiotics, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.